TONMYA Shows Significant Pain Reduction in Fibromyalgia Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy TNXP?
Source: Newsfilter
- Clinical Trial Results: At the 2026 Non-Opioid Pain Therapeutics Summit, TONMYA demonstrated a statistically significant reduction in weekly average pain scores at Week 14 (p<0.0001) compared to placebo in the RESILIENT study, with an effect size of 0.38, indicating its efficacy in treating fibromyalgia.
- Unique Dosing Method: TONMYA's sublingual formulation is designed for nighttime administration, bypassing first-pass metabolism to optimize drug exposure during sleep while limiting daytime exposure to the active metabolite, enhancing the overall treatment experience for patients.
- Good Tolerability: The study showed that TONMYA was well tolerated, with an adverse event-related discontinuation rate of 6.1%, lower than the 3.5% for placebo, and the most common adverse events were mild oral reactions, indicating a favorable safety profile.
- Market Demand Alignment: With over 10 million adults in the U.S. affected by fibromyalgia and existing treatments often limited by tolerability, the introduction of TONMYA provides an effective non-opioid alternative, addressing the urgent market need for new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNXP
Wall Street analysts forecast TNXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.940
Low
65.00
Averages
67.50
High
70.00
Current: 13.940
Low
65.00
Averages
67.50
High
70.00
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TONMYA Launches as New Treatment for Fibromyalgia
- Clinical Trial Results: At the 2026 American Academy of Pain Medicine Annual Meeting, Tonix Pharmaceuticals presented data from the Phase 3 RESILIENT trial involving 457 fibromyalgia patients, demonstrating statistically significant pain reduction over 14 weeks, with 30% of patients achieving clinically meaningful pain relief, underscoring the drug's efficacy and safety.
- Market Launch: TONMYA received FDA approval in August 2025 and was commercially launched in the U.S. in November 2025, marking it as the first new treatment for fibromyalgia in over 15 years, addressing the market's need for effective non-opioid analgesics and expected to enhance patient quality of life.
- Unique Drug Mechanism: TONMYA's sublingual formulation allows it to bypass first-pass hepatic metabolism, reducing the formation of the active metabolite norcyclobenzaprine, thereby enhancing the durability of treatment effects compared to traditional oral medications, making it suitable for long-term use.
- Impact on Patient Population: Fibromyalgia affects approximately 6 to 12 million adults in the U.S., with 90% being women; the introduction of TONMYA not only provides a new treatment option for patients but may also reduce reliance on existing medications, improving overall health outcomes and quality of life for those affected.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
TONMYA Receives FDA Approval for Fibromyalgia Treatment
- FDA Approval Milestone: TONMYA (cyclobenzaprine HCl sublingual tablets) received FDA approval on August 15, 2025, marking the first new treatment for fibromyalgia in adults in over 15 years, which is expected to significantly enhance patient quality of life and treatment options.
- Rapid Absorption Characteristics: The sublingual formulation of TONMYA utilizes a proprietary basifying agent to achieve rapid transmucosal absorption, resulting in a 154% increase in bioavailability compared to oral formulations, which will help patients achieve more durable analgesic effects during sleep while minimizing side effects.
- Clinical Trial Findings: In two Phase 1 clinical trials, TONMYA demonstrated good tolerability with all adverse events being mild or moderate, and no serious adverse events reported, establishing a solid foundation for its market introduction and acceptance.
- Significant Market Potential: Fibromyalgia affects approximately 6 to 12 million adults in the U.S., and the launch of TONMYA not only fills a critical gap in treatment options but also addresses the urgent need for long-term effective therapies, which is expected to drive revenue growth for the company.
See More
Tonix Pharmaceuticals to Present Tonmya at AAPM Annual Meeting
- New Drug Presentation: Tonix Pharmaceuticals will showcase its new drug Tonmya™ at the 2026 American Academy of Pain Medicine (AAPM) Annual Meeting, marking the first new treatment for fibromyalgia in over 15 years, which is expected to attract significant industry attention.
- Clinical Outcomes: Research indicates that TNX-102 SL produces clinically meaningful improvements in patient-centered outcomes, further validating its potential in treating fibromyalgia and potentially driving market demand.
- Conference Details: The poster will be presented on March 6, 2026, at 4:55 PM in Salt Lake City, with Dr. Errol Gould, Vice President of Medical Affairs at Tonix, as the presenter, likely drawing interest from numerous professionals.
- Product Line Expansion: Tonix is also conducting clinical trials for other drugs, including those targeting major depressive disorder and acute stress disorder, demonstrating the company's broad positioning in the CNS field and future growth potential.
See More
Tonix Pharmaceuticals Shares Decline Post Nasdaq Uplisting
- Nasdaq Uplisting: Tonix Pharmaceuticals commenced trading on the Nasdaq Global Select Market on March 3, 2026, reflecting compliance with higher financial and corporate governance standards, which may enhance visibility among institutional investors and improve liquidity.
- CEO Statement: CEO Seth Lederman emphasized that this uplisting is a significant milestone, indicating the company's commitment to driving growth and creating shareholder value, suggesting that Tonix has achieved notable financial and operational progress that could lead to increased trading volumes and better access to institutional investors.
- Stock Trend: Currently, Tonix Pharmaceuticals shares are down 2% at $13.70 during premarket trading, and the stock is trading 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term and reflecting ongoing challenges in the stock's performance.
- Technical Indicators: The relative strength index (RSI) is at 44.45, considered neutral, indicating that the stock is neither overbought nor oversold, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock, resulting in mixed momentum in performance.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, signifying the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is anticipated to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to higher trading volumes and a wider investor base.
- Strategic Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for Tonix, as the company aims to leverage this enhanced platform to drive growth and create value for shareholders, reflecting its financial and operational growth.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA providing the first new therapy for fibromyalgia in over 15 years, showcasing the company's potential in addressing high unmet medical needs.
See More
TONMYA Launches as New Treatment for Fibromyalgia
- Clinical Trial Results: At the 2026 American Academy of Pain Medicine Annual Meeting, Tonix Pharmaceuticals presented data from the Phase 3 RESILIENT trial involving 457 fibromyalgia patients, demonstrating statistically significant pain reduction over 14 weeks, with 30% of patients achieving clinically meaningful pain relief, underscoring the drug's efficacy and safety.
- Market Launch: TONMYA received FDA approval in August 2025 and was commercially launched in the U.S. in November 2025, marking it as the first new treatment for fibromyalgia in over 15 years, addressing the market's need for effective non-opioid analgesics and expected to enhance patient quality of life.
- Unique Drug Mechanism: TONMYA's sublingual formulation allows it to bypass first-pass hepatic metabolism, reducing the formation of the active metabolite norcyclobenzaprine, thereby enhancing the durability of treatment effects compared to traditional oral medications, making it suitable for long-term use.
- Impact on Patient Population: Fibromyalgia affects approximately 6 to 12 million adults in the U.S., with 90% being women; the introduction of TONMYA not only provides a new treatment option for patients but may also reduce reliance on existing medications, improving overall health outcomes and quality of life for those affected.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
TONMYA Receives FDA Approval for Fibromyalgia Treatment
- FDA Approval Milestone: TONMYA (cyclobenzaprine HCl sublingual tablets) received FDA approval on August 15, 2025, marking the first new treatment for fibromyalgia in adults in over 15 years, which is expected to significantly enhance patient quality of life and treatment options.
- Rapid Absorption Characteristics: The sublingual formulation of TONMYA utilizes a proprietary basifying agent to achieve rapid transmucosal absorption, resulting in a 154% increase in bioavailability compared to oral formulations, which will help patients achieve more durable analgesic effects during sleep while minimizing side effects.
- Clinical Trial Findings: In two Phase 1 clinical trials, TONMYA demonstrated good tolerability with all adverse events being mild or moderate, and no serious adverse events reported, establishing a solid foundation for its market introduction and acceptance.
- Significant Market Potential: Fibromyalgia affects approximately 6 to 12 million adults in the U.S., and the launch of TONMYA not only fills a critical gap in treatment options but also addresses the urgent need for long-term effective therapies, which is expected to drive revenue growth for the company.
See More
Tonix Pharmaceuticals to Present Tonmya at AAPM Annual Meeting
- New Drug Presentation: Tonix Pharmaceuticals will showcase its new drug Tonmya™ at the 2026 American Academy of Pain Medicine (AAPM) Annual Meeting, marking the first new treatment for fibromyalgia in over 15 years, which is expected to attract significant industry attention.
- Clinical Outcomes: Research indicates that TNX-102 SL produces clinically meaningful improvements in patient-centered outcomes, further validating its potential in treating fibromyalgia and potentially driving market demand.
- Conference Details: The poster will be presented on March 6, 2026, at 4:55 PM in Salt Lake City, with Dr. Errol Gould, Vice President of Medical Affairs at Tonix, as the presenter, likely drawing interest from numerous professionals.
- Product Line Expansion: Tonix is also conducting clinical trials for other drugs, including those targeting major depressive disorder and acute stress disorder, demonstrating the company's broad positioning in the CNS field and future growth potential.
See More
Tonix Pharmaceuticals Shares Decline Post Nasdaq Uplisting
- Nasdaq Uplisting: Tonix Pharmaceuticals commenced trading on the Nasdaq Global Select Market on March 3, 2026, reflecting compliance with higher financial and corporate governance standards, which may enhance visibility among institutional investors and improve liquidity.
- CEO Statement: CEO Seth Lederman emphasized that this uplisting is a significant milestone, indicating the company's commitment to driving growth and creating shareholder value, suggesting that Tonix has achieved notable financial and operational progress that could lead to increased trading volumes and better access to institutional investors.
- Stock Trend: Currently, Tonix Pharmaceuticals shares are down 2% at $13.70 during premarket trading, and the stock is trading 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term and reflecting ongoing challenges in the stock's performance.
- Technical Indicators: The relative strength index (RSI) is at 44.45, considered neutral, indicating that the stock is neither overbought nor oversold, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock, resulting in mixed momentum in performance.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, signifying the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is anticipated to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to higher trading volumes and a wider investor base.
- Strategic Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for Tonix, as the company aims to leverage this enhanced platform to drive growth and create value for shareholders, reflecting its financial and operational growth.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA providing the first new therapy for fibromyalgia in over 15 years, showcasing the company's potential in addressing high unmet medical needs.
See More
